Analyst Price Targets — SNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2025 10:07 am | Sarita Kapila | Morgan Stanley | $56.00 | $49.19 | TheFly | Sanofi resumed with an Equal Weight at Morgan Stanley |
| September 10, 2024 5:42 am | Luisa Hector | Berenberg Bank | $64.00 | $58.51 | TheFly | Sanofi price target raised to $64 from $56 at Berenberg |
| July 26, 2024 7:33 am | Jasper Hellweg | Argus Research | $60.00 | $52.54 | StreetInsider | Sanofi-Aventis (SNY) PT Raised to $60 at Argus |
| April 3, 2024 12:55 pm | Jasper Hellweg | Argus Research | $55.00 | $48.00 | StreetInsider | Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD' |
| December 21, 2022 1:30 pm | Iain Simpson | Barclays | $48.07 | $48.17 | TheFly | Sanofi confirms to Bloomberg Zantac settlement in California |
Latest News for SNY
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Becker Capital Management Inc. cut its holdings in shares of Sanofi (NASDAQ: SNY) by 8.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 522,681 shares of the company's stock after selling 45,719 shares during the quarter. Becker Capital Management
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi's commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug…
Citigroup Inc. reduced its holdings in shares of Sanofi (NASDAQ: SNY) by 48.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,253 shares of the company's stock after selling 226,396 shares during the quarter. Citigroup Inc.'s holdings in Sanofi were
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.